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Abstract
Background: Breast cancer consists of a variety of tumours, which differ by their morphological features, molecular
characteristics and outcome. Well-known prognostic factors, e.g. tumour grade and size, Ki-67, hormone receptor
status, HER2 expression, lymph node status and patient age have been traditionally related to prognosis. Although
the conventional prognostic markers are reliable in general, better markers to predict the outcome of an individual
tumour are needed.
Matrix metalloproteinase-1 (MMP-1) expression has been reported to inversely correlate with survival in advanced
cancers. In breast cancer MMP-1 is often upregulated, especially in basal-type breast tumours. The purpose of this
retrospective study was to analyse MMP-1 expression in breast cancer cells and in cancer associated stromal cells
and to correlate the results with traditional prognostic factors including p53 and bcl-2, as well as to patient survival
in breast cancer subtypes.
Methods: Immunohistochemical analysis of MMP-1, ER, PR, Ki-67, HER2, bcl-2, p53 and CK5/6 expression was performed
on 125 breast cancers. Statistical analyses were carried out using Kruskal-Wallis and Mann-Whitney -tests. In pairwise
comparison Bonferroni-adjustment was applied. Correlations were calculated using Spearman rank-order correlation
coefficients. Kaplan-Meier survival analyses were carried out to compare breast cancer-specific survival curves. Factors
significantly associated with disease-specific survival in univariate models were included in multivariate stepwise.
Results: Positive correlations were found between tumour grade and MMP-1 expression in tumour cells and in
stromal cells. P53 positivity significantly correlated with MMP-1 expression in tumour cells, whereas HER2 expression
correlated with MMP-1 both in tumour cells and stromal cells. MMP-1 expression in stromal cells showed a significant
association with luminal A and luminal B, HER2 overexpressing and triple-negative breast cancer subtypes.
Conclusions: The most important finding of this study was the independent prognostic value of MMP-1 as well as
Ki-67 and bcl-2 expression in tumour cells. Our study showed also that both tumoural and stromal MMP-1
expression is associated with breast tumour progression and poor prognosis. A significant difference of MMP-1
expression by cancer associated stromal cells in luminal A, luminal B and triple-negative breast cancer classes was
also demonstrated.
Please see related commentary article http://www.biomedcentral.com/1741-7015/9/95
Background
Breast cancer consists of a variety of tumour types, which
differ by their morphology, molecular characteristics and
clinical outcome. It is the leading cause of cancer death
among women aged 20-59 years in high-income coun-
tries [1]. The prognostic factors that indicate disease
outcome include tumour grade and size, proliferation
index Ki-67, hormone receptor status, HER2 expression,
lymph node status and patient age. In addition, several
markers including p53 [2] and bcl-2 [3,4] expression have
been shown to associate with survival.
The current breast cancer classification is based on
morphological features [5]. Newer approaches to mole-
cular classification by gene expression profiling have
identified five distinct subclasses [6,7]. Two of them are
ER positive (luminal A and B) and three ER negative
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types) with different prognoses and treatment responses
to current therapies. Basal-like cancers are negative for
hormone receptors, but positive for basal cytokeratins.
Triple-negative breast cancers lack expression of HER2,
estrogen and progesterone receptors. The majority of
triple-negative breast cancers carry the basal-like mole-
cular profile [8].
Although well-documented classical prognostic mar-
kers are reliable in general, better markers to predict the
outcome of an individual tumour are needed. It would be
especially important to identify patients with favourable
outcome and to save them from treatment side-effects.
On the other hand, tumours that have capability to
metastasize need targeted treatment and intensified
follow-up.
Tumour invasion and metastasis is a multistage pro-
cess, which includes tumour growth, local proteolysis
and migration of the tumour cells through the degraded
tissue [9]. All these steps involve interaction between
tumour cells and the extracellular matrix (ECM). Local
proteolysis is carried out by proteinases produced by the
tumour cells or by the surrounding stromal cells. Matrix
metalloproteinases (MMPs) are a family of enzymes
consisting of 28 members [10] capable of degrading
essentially all macromolecules of the ECM [11]. The
activity of MMPs is controlled extracellularly by tissue
inhibitors of matrix metalloproteinases (TIMPs) [12].
A number of studies have demonstrated a correlation
between MMP expression and the invasive potential of
human cancer [13]. Furthermore, the ratio of MMPs to
TIMPs has been related to the prognosis of several
human tumours, including breast cancer [14,15]. Recent
studies have also shown that MMPs’ functional genetic
polymorphisms may contribute to breast cancer risk
[16]. In most malignant tumours, stromal fibroblasts
have been shown to be the predominant source of
MMPs [17], but there is also evidence that MMPs are
produced by cancer cells [18].
MMP-1 has been described in a wide range of
advanced cancers with a significant negative correlation
with survival [18,19]. MMP-1 is often upregulated in
breast cancer, especially in basal-type tumours [20], and
is supposed to be critically involved in metastatic disse-
mination [21,22]. Recent reports suggest that MMP-1
associates with a shortened relapse free survival [23] and
poor outcome in breast cancer [20].
In most previous studies MMP-1 expression has been
analyzed at mRNA rather than at protein level. There-
fore, the purpose of this retrospective study was to ana-
lyse the exact location of MMP-1 expression both in
breast cancer cells as well as in cancer associated stro-
mal cells and to correlate the results with traditional
prognostics factors and with bcl-2 and p53 expression
in different breast cancer subtypes. In addition, we
wanted to correlate MMP-1 expression to breast cancer-
specific survival during an extensive follow-up time.
Methods
Patients and tissue material
The material consisted of 118 female breast cancer
patients whose tissue samples were available (mean age
at surgery was 57,5 years, range 30-90 years) and who
were operated and treated at Turku University Central
Hospital during 1985-1994. In addition, to increase the
number of basal-like subtype seven patients operated in
2007 were included in the study. Due to the retrospective
nature of the study, informed consents could not be
obtained from individual patients. The permission to use
the tissue material without informed content was given
by the local and national regulatory authorities, Turku
University Hospital Ethics committee (no 241/2005) and
the Finnish National Authority for Medicolegal Affairs
(no 4424/32/300/02). Follow-up information on life sta-
tus was collected for each case (Central Statistical Office
of Finland). Tumour characteristics including tumour
size, grade and lymph node status were obtained from
the pathology database (Table 1). None of the patients
received radiation or chemotherapy before operation. All
breast tumours were invasive carcinomas and most of
them were symptomatic.
Four μm thick serial sections from formalin-fixed, par-
affin-embedded tumour tissue were cut and stained with
haematoxylin and eosin. Slides were reviewed to confirm
the diagnosis. The tumour histology was assessed
according to the WHO classification [5] and tumour
grading (I-III) was based on the recommendations made
by Elston and Ellis 1991 [24].
Immunohistochemistry
Immunohistochemical staining of MMP-1, ER, PR, Ki-67,
HER2, bcl-2, p53 and CK5/6 was carried out with Tech-
Mate 500+ immunostainer using monoclonal antibodies
and a peroxidase/diaminobenzidine LSAB+ or EnVision
detection kit (DAKO). Immunodetection of MMP-1 was
performed using mouse monoclonal MMP-1 antibody
(Onkogene) with dilution 1:100 and 10 mM TRIS-HCl
with 1 mM EDTA (pH9) as a pretreatment. Immunohis-
tochemical staining of ER, PR, Ki-67, HER2, bcl-2, p53
and CK5/6 were performed as described [25]. The used
MMP-1 antibody recognises both the latent and the
active forms of MMP-1 protein.
MMP-1 (Figures 1a-e), p53, HER2, ER, PR, Ki-67 and
bcl-2 staining was evaluated from cells at the border of
the most cellular part of the tumour. Areas showing
necrosis or inflammation were excluded from the analy-
sis. For MMP-1 expression the number of immunoposi-
tive tumour cells per 100 malignant cells (0-100%) from
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objective independently by two observers (PB, PH) with-
out any knowledge of the clinical data and the mean
value of immunopositive areas was recorded. In addition
to tumour cells MMP-1 staining in non-lymphoid stro-
mal cells was evaluated in the same way. The percentage
of tumour cells with nuclear staining for hormonal
receptors, Ki-67 and p53 was also recorded. For bcl-2,
cytoplasmic staining was scored and the percentage of
positive tumour cells was recorded. HER2 expression was
evaluated as membrane staining of invasive tumour cells
and scored to four classes (0/1+/2+/3+). Triple-negative
cases (ER-, PR- and HER2-) were stained with basal cyto-
keratin CK5/6, and expression was considered as positive,
if at least 10% of the cancer cells showed cytoplasmic
and/or membranous staining.
Statistical analyses
Statistical analyses were carried out using Kruskal-
Wallis and Mann-Whitney -tests. In pairwise compari-
son Bonferroni-adjustment was applied. Correlations
were calculated using Spearman rank-order correlation
coefficients. Non-parametric test was applied because of
non-normal distribution of responses.
Breast cancer-specific survival time was determined from
time of diagnosis until death from breast cancer. Patients
w h ow e r ea l i v ea tt h ee n do ft h ef o l l o w - u po nO c t o b e r
2009 or died of other causes were used as censored values
in survival analyses. Kaplan-Meier survival analyses were
carried out to compare breast cancer-specific survival
curves. Univariate Cox regression model was used to
examine prognostic factors for breast cancer-specific survi-
val. Factors significantly associated with disease-specific
survival in univariate models were included in multivariate
stepwise (inclusion and exclusion criteria p = 0.05) Cox
regression model. Results are expressed using hazard ratios
(HR) with 95% confidence intervals (CI) and P-values less
than 0.05 were considered as significant. The statistical
analyses were carried out using SAS/STAT(r) software,
Version 9.1.3 SP4 of the SAS System for Windows.
Cox univariate method was used to calculate breast
cancer-specific survival analysis for 118 patients. The
seven patients from this century were not included in
survival data, because their treatment might have been
different from earlier decades and because of the short
follow-up. To examine interactions of different prognos-
t i cf a c t o r si nam u l t i v a r i a t ea n a l y s i s ,w eu s e dt h eC o x
regression model. Parameters that achieved statistical
significance for disease-specific survival in the log-rank
test were included in the multivariate analysis.
Results
Immunohistochemical staining and statistical analyses
MMP-1 positivity in tumour cells and in stromal cells
was observed in all analyzed tumours. The MMP-1
expression in tumour cells ranged from 10% to 95% and
in stromal cells from 5% to 80%. In tumour cells the
MMP-1 expression was positive in 7.2% with value ≤
30%, in 8% with value ≤ 50%, in 31.2% with value ≤ 70%
and in 53.6% with value over 70%. The MMP-1 positivity
was lower in stromal cells, where 47.6% of cases were
Table 1 Patients and tumour characteristics
Variable Number of patients (%)
Number of the patients 125 (aged 30-90, mean
57, 5)
Grade
I 10 (8%)
II 66 (52, 8%)
III 49 (39, 2%)
Axillary nodal status
N0 64 (51, 2%)
≥N1 50 (40%)
Unknown 11 (8, 8%)
Estrogen receptor status (ER)
1)
Positive 80 (64%)
Negative 45 (36%)
Progesterone receptor status (PR)
1)
Positive 82 (65, 6%)
Negative 43 (34, 4%)
Ki-67 status
2)
low ≤ 15% 63 (50,4%)
intermediate 16-30% 41 (32,8%)
high > 30% 20 (16%)
one value missing 1 (8%)
Histologic type
Ductal 110 (88%)
Lobular 10 (8%)
Subtypes 5 (4%)
Her2
3)
IHC positive (2+ and 3+) 25 (20%)
IHC negative (0 and 1+) 100 (80%)
CK 5/6
4)
Triple-negative (ER-, PR-, Her2-) 35 (28%)
Basal-like carcinoma (ER-, PR-, Her2-,
CK5/6+)
20 (16%)
Treatment after operation
Chemotherapy 27 (21,6%)
Radiation 59 (47,2%)
Hormonal therapy 24 (19,2%)
1,4) Cut off point used for ER and PR immunohistochemistry is 10% of
positively stained tumour nuclei and 10% cytoplasmic staining for CK5/6.
2) Proliferation index according to St Gallen Consesus (Goldhirsch et al 2009).
3) Scoring of HER2 immunohistochemistry: Score 0: no staining is observed or
cell membrane staining is observed in less than 10% of tumour cells. Score 1
+: a faint perceptible membrane staining can be detected in more than 10%
of the tumour cells or cells are only stained in part of their membrane. Score
2+: a weak to moderate complete membrane staining is observed in more
than 10% of the tumour cells. Score 3+: a strong complete membrane
staining is observed in more than 10% of the tumour cells.
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50%, 30.6% positive with value ≤ 70% and 7.3% positive
with value over 70%. A positive correlation was seen
between tumour grade and MMP-1 expression in tumour
cells (r = 0.23, p = 0.0101, Figure 2) and in stromal cells
(r = 0.21, p = 0.0170, Figure 2), the higher grade tumours
showing stronger MMP-1 positivity.
The association between MMP-1 expression and tradi-
tional prognostic factors was evaluated. HER2 immunor-
eactivity correlated with MMP-1 positivity both in stromal
cells (r = 0.25, p = 0.0050) and tumour cells (r = 0.22, p =
0.0121). Using a dicotomised HER2 grouping into immu-
nonegative (0 - 1+ classes) and immunopositive (2+ - 3+
classes) groups, we also found a significant positive asso-
ciation between HER2 and MMP-1 expression in tumour
cells (p = 0.0086) and in stromal cells (p = 0.0038). MMP-
1 positivity in cancer cells or in stromal cells did not show
significant correlation with estrogen or progesterone
receptors. P53 had a significant positive correlation with
MMP-1 expression in tumour cells (r = 0.23, p = 0.0113),
but not in stromal cells. Ki-67 or Bcl-2 did not show any
significant correlation with MMP-1 staining in tumour
cells or in stromal cells.
We further evaluated the association between MMP-1
expression and the different molecular breast cancer
subtypes. MMP-1 positivity in stromal cells showed sig-
nificant differences (p = 0.0129) between breast cancer
subtypes. In luminal B subtype, the MMP-1 expression
in stromal cells was higher than in luminal A subtype (p
= 0.0258), and also the luminal B subtype stromal cells
showed higher MMP-1 positivity than triple-negative
breast cancer cells (p = 0.0336) (Figure 3). MMP-1
expression in cancer cells did not show any association
with these breast cancer subtypes. No association with
MMP-1 positivity in tumour cells or in stromal cells
was found when tumours were divided to triple-negative
and non-triple-negative groups. Nor was any association
found, when basal-like and non-basal-like groups and
MMP-1 expression in tumour cells or in stromal cells
were analyzed.
Figure 1 Immunohistochemical staining of MMP-1 in breast cancer. a-b) Immunohistochemical staining of MMP-1 in infiltrating ductal
carcinoma GIII. The staining is observed both in nuclei and in the cytoplasm. c) Breast carcinoma cells with positive MMP-1 nuclear staining and
with d) positive nuclear and cytoplasm staining and with e) positive tumour cells and cancer associated stromal cells.
Boström et al. BMC Cancer 2011, 11:348
http://www.biomedcentral.com/1471-2407/11/348
Page 4 of 8Survival analysis
The median follow-up period of the survived patients was
20 years (range, from 17 to 24 years). From the patients
included in the survival analyses 44 patients (37%) were
still alive, 51 (43%) had died from breast cancer and 23
(19%) from some other cause during the follow up time.
There was a statistically significant difference in breast
cancer-specific survival between tumours with high vs.
low expression of MMP-1 in tumour cells (cut-off value
70%, p = 0.0171) (Figure 4), tumour grade I vs. III (p =
0.0099), triple-negative vs. non-triple-negative breast
cancers (p = 0.0137), basal-like vs. non-basal-like breast
cancers (p = 0.0103), low vs. high bcl-2 expression (cut-
off value 25%, p = 0.0003) and high vs. low estrogen
receptor expression (cut-off value 10%, p = 0.0013). The
difference in breast cancer-specific survival between
Ki-67 subcategories (≤15% and > 15%) were also statisti-
cally significant (p = 0.0022). There was no statistically
significant difference in breast cancer-specific survival
between MMP-1 positivity in stromal cells with any cut-
off value (Figure 4). Neither did patient age or p53
expression associate with breast cancer-specific survival.
The potential independent prognostic value of MMP-1
p r o t e i ne x p r e s s i o ni nt u m o u rc e l l sw a se v a l u a t e db y
stepwise Cox regression analysis. Ki-67 expression and
high MMP-1 positivity in tumour cells (cut-off 70%)
were significantly associated with poor breast cancer-
specific survival (Table 2). Positive bcl-2 status was a
significant positive prognostic factor for breast cancer-
specific survival (Table 2).
Discussion
Invasion of tumour cells is a multistep process that
involves proteolytic activity and migration of tumours
cells through the degraded ECM. The expression of
MMP-1 is characteristic for many types of malignant
tumours, including breast cancer. Upregulation of MMP-
1 was recently indicated to associate with poor outcome
in breast cancer [20]. In this study, we evaluated MMP-1
expression by immunohistochemistry using original tis-
sue sections instead of tissue microarrays, and correlated
it with different breast cancer subtypes and with tradi-
tional prognostics factors and patient survival.
Our results demonstrate MMP-1 positivity both in the
nuclei and in the cytoplasm of breast cancer cells and in
the stromal cells, often termed as cancer-associated fibro-
blasts (CAFs). Our results showed a higher MMP-1
expression in tumour cells than in stromal cells. Earlier
studies have demonstrated elevated nuclear MMP-1
expression in tumour cells [26], as well as in stromal
fibroblasts [15,23,27]. Yet the results are conflicting and
can be explained by the use of different tissue handling,
fixation and incubation conditions as well as different
antibodies used [28]. Also the scoring criteria for each
antibody should be standardized. The antibody we used
recognises both the latent and active forms of MMP-1
protein.
In our study, MMP-1 expression in tumour cells and
in stromal cells showed a significant association with
tumour grade. This finding is partially in line with pre-
vious data [29], where CAFs showed a correlation with
tumour stage. Earlier studies have also shown elevation
Figure 2 Correlation between tumour grade and MMP-1
immunoreactivity. The histograms present an association between
the histological grade of the breast cancer and the
immunohistochemical expression of MMP-1. P-values for MMP-1
expression in tumour cells: overall p = 0.023, grade I vs. II p = 1.0,
grade I vs. III p = 0.81, grade II vs. III p = 0.0177. P-values for MMP-1
expression in stromal cells: overall p = 0.0493, grade I vs. II p =
0.4839, grade I vs. III p = 0.1008, grade II vs. III p = 0.2637.
Figure 3 MMP-1 immunoreactivity of stromal cells of various
breast cancer subtypes. Immunohistochemically detected
expression of MMP-1 in stromal cells with significant differences in
breast cancer subtypes. P-values for overall difference p = 0.0129,
luminal A vs. luminal B p = 0.0258, luminal A vs. Her2 p = 0.8334,
luminal A vs. triple-negative p = 1.00, luminal B vs. Her2 p = 0.3792,
luminal B vs. triple-negative p = 0.0336.
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pared to low-grade tumours [20,30], but also opposite
results on MMP-1 immunohistochemical expression and
tumour grade exist [28].
In previous studies high expression on MMP-1 by
stromal cells correlated with the occurrence of metasta-
sis [23] suggesting that tumoural stromal tissue is
important in cancer progression [31]. In our study, the
expression of MMP-1 both in tumour cells and in stro-
mal cells and especially the correlation between the
expression and tumour grade may indicate an impact of
MMP-1 on cellular properties such as growth, death,
and migration [32]. MMPs are known to cleave not only
structural components of the ECM, but also growth fac-
tor precursors, cell surface receptors, cytokines and cell
adhesion molecules [18,33].
Hormone receptors are associated with a favourable
prognosis and predict response to endocrine treatment
[34]. In our analysis the MMP-1 positivity did not show
any correlation with hormone receptors. However, we
found a negative, but not a significant correlation
between tumour cell MMP-1 expression and ER expres-
sion. MMP-1 expression has previously been reported to
be significantly increased in ER-negative breast cancer
[20,35]. In a previous study MMP-1 expression and PR
expression had a statistically significant inverse correla-
tion with CAFs and cancer cells [29]. Also the positive
correlation between HER2 and MMP-1 expression both
in tumour cells and stromal cells in our study shows that
MMP-1 is associated with poor outcome in breast cancer.
Our result showing the correlation between p53 and
MMP-1 expression in tumour cells is in accordance with
tumour aggressiveness.
One important finding of the present study is the sig-
nificantly different MMP-1 expression in stromal cells of
different breast cancer subtypes (Figure 3). In our study
MMP-1 overexpression in tumour cells did not have any
significant differences within breast cancer subtypes. On
the other hand, we did not find any association between
luminal or basal-like breast tumours and MMP-1 positiv-
ity in tumour cells. Similar results have been presented
by González [36]. However, MMP-1 mRNA is shown to
Figure 4 Influence of MMP-1 expression in tumour cells and in stromal cells on survival among women with breast cancer.
Table 2 Disease specific- survival analysis at 24 years follow-up
Variable n HR (95%CI) p (univariate) HR (95%CI) p (multivariate)
ER > 10% 118 0.41 (0.24-0.72) 0.0018*
PR > 10% 118 0.71 (0.40-1.25) 0.2322
Ki-67 > 15% 117 2.35 (1.34-4.13) 0.0030* 2.01 (1.12-3.59) 0.0186*
Bcl-2 > 25% 118 0.33 (0.18-0.63) 0.0007* 0.45 (0.23-0.86) 0.0158*
Triple-neg 118 2.05 (1.15-3.68) 0.0158*
Basal-type 118 2.34 (1.20-4.58) 0.0127*
p53 > 10% 118 1.73 (0.98-3.06) 0.0601
MMP-1 tumour cells > 70% 118 1.99 (1.12-3.53) 0.0194* 1.81 (1.01-3.22) 0.0438*
MMP-1 fibroblasts > 30% 118 1.35 (0.77-2.39) 0.2948
HR = Hazard Ratio
P-value less than 0.05 (*) were considered as significant.
Tumour grade was not included in disease specific -survival analysis, because none of grade I patients died of breast cancer.
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pared with non-basal-type breast cancers [20].
Few studies have correlated MMP-1 expression with
breast cancer-specific survival. In our study the follow up
-time for breast cancer-specific survival was extensively
long being over 20 years. We found that MMP-1 positiv-
ity in tumour cells with a 70% cut-off level had a signifi-
cant association with survival in univariate analyses
(Figure 4). The breast cancer-specific survival curve con-
tinued to decrease even during the extended follow-up
period. In addition, tumour grade, triple-negative and
basal-like breast cancers, ER, Ki-67 and bcl-2, were asso-
ciated with breast cancer-specific survival in our study. In
a multivariate analysis the presence of MMP-1 positivity
in tumour cells had an independent prognostic value as
did Ki-67 and bcl-2 immunoreactivity. No statistically
significant difference was found in breast cancer-specific
survival in the expression of MMP-1 in stromal cells with
any cut-off values (Figure 4).
Conclusions
In summary, our study shows that both tumoural and
stromal MMP-1 positivity is associated with breast
tumour progression and poor prognosis. Our findings
show a significant difference in MMP-1 positivity of can-
cer associated stromal cells between luminal A, luminal B
and triple-negative breast cancer types. The most impor-
tant finding of the present work is that the MMP-1
expression of tumour cells carries an independent prog-
nostic value in breast cancers. These results suggest that
MMP-1 expression of both stromal and tumour cells
may control breast cancer progression. Further investiga-
tion with larger patient cohorts is needed to better
understand the function of MMP-1 in tumour cells.
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